AstraZeneca Weighs Expanding Fasenra to COPD after Phase III Failure

AstraZeneca said it will await results from a second Phase III trial assessing Fasenra™ (benralizumab) in chronic obstructive pulmonary disease (COPD) before deciding whether to continue developing the drug in that indication—after acknowledging that the respiratory drug has failed the first pivotal study.Fasenra missed its primary endpoint in the GALATHEA Phase III trial ( NCT02138916 ) of a statistically significant reduction of exacerbations in patients with COPD. AstraZeneca offe